Methylation at CpG2 in the CD95L promoter region in both newly diagnosed and recurrent GBM as well as CD95L protein expression in newly diagnosed GBM has been indicated to be associated with the treatment efficacy of asunercept [19,20]. Here, FASLG is linked to glioblastoma.